

PEDIATRICS

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents: Policy Statement

Committee on Infectious Diseases

DOI: 10.1542/peds.2025-073924

Journal: *Pediatrics*

Article Type: AAP Policy Statement

Citation: American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents: Policy Statement. *Pediatrics*. 2025; doi: 10.1542/peds.2025-073924

This is a prepublication version of an article that has undergone peer review and been accepted for publication but is not the final version of record. This paper may be cited using the DOI and date of access. This paper may contain information that has errors in facts, figures, and statements, and will be corrected in the final published version. The journal is providing an early version of this article to expedite access to this information. The American Academy of Pediatrics, the editors, and authors are not responsible for inaccurate information and data described in this version.

AMERICAN ACADEMY OF PEDIATRICS

POLICY STATEMENT

Organizational Principles to Guide and Define the Child Health System and/or Improve the Health of All Children

Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents: Policy Statement

Committee on Infectious Diseases

INTRODUCTION

This policy statement updates the recommendations of the American Academy of Pediatrics (AAP)¹ for the use of coronavirus disease 2019 (COVID-19) vaccines in the prevention of severe COVID-19 in children. These COVID-19 vaccine recommendations may change in future seasons or as additional variants emerge. These recommendations for the use of 2025-2026 COVID-19 vaccine are contingent upon the approval by the US Food and Drug Administration of updated COVID-19 vaccine products.

COVID-19 continues to be a cause of hospitalization^{2,3} and death⁴ in the pediatric population. COVID-19 vaccines are safe⁵⁻¹² and effective¹³ in protecting individuals and populations against serious outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, including post-acute sequelae of SARS-CoV-2 infection (PASC)¹⁴ and multisystem inflammatory syndrome in children (MIS-C).¹⁵

RECOMMENDATIONS

- Infants and children 6 through 23 months of age are at high risk for severe COVID-19.^{2,4} The AAP recommends all infants and children in this age group who do not have contraindications* receive 2025-2026 COVID-19 vaccine, as follows:
 - Those who are previously unvaccinated should receive an initial vaccine series.

* COVID-19 vaccine contraindication includes a history of severe allergic reaction (eg, anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine.

- Those who are previously vaccinated but did not complete their initial vaccine series should complete their initial vaccine series.
- Those who are previously vaccinated and completed their initial series should receive a single dose. This dose should be administered at least 8 weeks after the last dose was received.
- Those with a previous asymptomatic infection or symptomatic disease caused by SARS-CoV-2 should also receive COVID-19 vaccination.
- Children 6 months through 18 years of age who are moderately or severely immunocompromised require 2 or more doses of age-appropriate 2025-2026 COVID-19 vaccine depending on previous vaccination status.¹⁶ Refer to the [AAP Recommended Child and Adolescent Immunization Schedule](#) for dosing recommendations.
- The AAP recommends a single dose of age-appropriate 2025-2026 COVID-19 vaccine for all children and adolescents 2 through 18 years of age in the following risk groups (as described in Table 1) regardless of prior COVID-19 vaccination status:
 - Persons at high risk of severe COVID-19²
 - Residents of long-term care facilities or other congregate settings
 - Persons who have never been vaccinated against COVID-19
 - Persons whose household contacts are at high risk for severe COVID-19^{2,17}
- Children 2 through 18 years of age not included in the risk groups above whose parent or guardian desires their protection from COVID-19 should be offered a single dose of age-appropriate 2025-2026 COVID-19 vaccine.¹⁸ This dose should be administered at least 8 weeks after the last dose was received.
- Any available COVID-19 vaccine appropriate by age and health status that is approved by the US Food and Drug Administration through a biologics license application or authorized through emergency use authorization can be used. The most updated version of the COVID-19 vaccine that is available should be used.

For additional clinical guidance on COVID-19, refer to the [Red Book: 2024 Report of the Committee on Infectious Diseases](#). For more information on the dosing and administration of COVID-19 vaccines, storage and handling, reporting, and patient education, visit <https://www.aap.org/en/patient-care/covid-19/>.

This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication.

Policy statements from the American Academy of Pediatrics benefit from expertise and resources of liaisons and internal (AAP) and external reviewers. However, policy statements from the American Academy of Pediatrics may not reflect the views of the liaisons or the organizations or government agencies that they represent.

The guidance in this statement does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

All policy statements from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

FUNDING: No external funding.

FINANCIAL/CONFLICT OF INTEREST DISCLOSURE: Sean O'Leary, MD, MPH, FAAP, has no potential conflicts of interest to disclose. José Romero, MD, FAAP, has disclosed a financial relationship with Pfizer in an advisory role regarding COVID-19 vaccination for adults. Robert W. Frenck Jr., MD, FAAP, disclosed relationships with Pfizer and Moderna. Neither Dr. Romero nor Dr. Frenck participated in making recommendations or development of this statement. Other disclosures of committee members were reviewed and determined not relevant to the work related to the statement.

Table 1. Populations Recommended for Vaccination Including Those at High Risk for Severe COVID-19 Among Children Aged 6 Months Through 18 Years*

Population Characteristics	
Infants and children 6 through 23 months of age	
Residents of long-term care facilities or other congregate settings ^a	
Children who have never been vaccinated against COVID-19	
Infants and children with household contacts who are at high risk for severe COVID-19 ^{2,7}	
Underlying Condition or Treatment With Common Examples^b	
Chronic pulmonary disease	Asthma/reactive airway disease Chronic lung disease of prematurity Compromised respiratory function (eg, abnormality of airway, tracheostomy, or ventilator dependent)
Cardiovascular disease	Congenital heart disease
Gastrointestinal disorders	Feeding tube dependent Inflammatory bowel disease
Hepatic disease	Chronic liver disease
Hematologic disease	Sickle cell disease
Metabolic disorders	Diabetes mellitus
Obesity	BMI \geq the 95 th percentile in children
Neurologic and neurodevelopmental conditions	Cerebral palsy Epilepsy Intellectual developmental disorder Compromised mobility (eg, wheelchair dependent)
Immunosuppressive conditions ^c	Receipt of immunosuppressive therapy Primary immunodeficiency HIV infection Receipt of hematopoietic cell transplant or solid organ transplant
Rheumatologic, autoimmune disease	Systemic lupus erythematosus Juvenile idiopathic arthritis

^a Congregate care settings refer to places where individuals live together in structured environments outside of their home, including residential treatment facilities, group homes, emergency shelters, juvenile detention centers, etc.

^b List of examples is not exhaustive.

^c Children who are **moderately or severely immunocompromised require 2 or more doses** of COVID-19 vaccine. Additional doses may be administered at ≥ 2 month intervals, informed by the clinical judgment of a health care provider and personal preference and circumstances.¹⁶ Refer to [AAP Recommended Child and Adolescent Immunization Schedule](#) for dosing guidance.

* Adapted from Free RJ, Patel K, Taylor CA, et al. Hospitalization for COVID-19 and risk factors for severe disease among children: 2022-2024. *Pediatrics*. Published online July 3, 2025. DOI: 10.1542/peds.2025-072788.²

COMMITTEE ON INFECTIOUS DISEASES, 2025-2026

Sean T. O’Leary, MD, MPH, FAAP, Chairperson
James D. Campbell, MD, MS, FAAP, Vice Chairperson
Monica I. Ardura, DO, MSCS, FAAP
Kristina A. Bryant, MD, FAAP, *Red Book Online* Team Lead
Roberta L. DeBiasi, MD, MS, FAAP
Claudia Espinosa, MD, MSc, FAAP
Robert W. Frenck, Jr, MD, FAAP
C. Mary Healy, MD
Betsy C. Herold, MD, FAAP
Chandy C. John, MD, MS, FAAP
Aaron M. Milstone, MD, MHS, FAAP
Angela L. Myers MD, MPH, FAAP
Pia S. Pannaraj, MD, MPH, FAAP
Adam J. Ratner, MD, MPH, FAAP, *Red Book* Associate Editor
José R. Romero, MD, FAAP
Matthew Zahn, MD, FAAP

EX-OFFICIO

David W. Kimberlin, MD, FAAP, *Red Book* Editor
Ritu Banerjee, MD, PhD, FAAP, *Red Book* Associate Editor
Elizabeth D. Barnett, MD, FAAP, *Red Book* Associate Editor
Ruth Lynfield, MD, FAAP, *Red Book* Associate Editor

LIAISONS

Amina Ahmed, MD, FAAP, American Thoracic Society
Michelle Barton, MD, Canadian Paediatric Society
Carolyn Cleary, MD, FAAP, AAP Committee on Practice and Ambulatory Medicine
Deneé J. Moore, MD, American Academy of Family Physicians
Jennifer L. Thompson, MD, American College of Obstetricians and Gynecologists
Juan P. Torres, MD, PhD, Sociedad Latinoamericana de Infectología Pediátrica
Charles R. Woods, Jr., MD, MS, FAAP, Pediatric Infectious Diseases Society

STAFF

Gillian Gibbs, MPH
Sunnah Kim

ACKNOWLEDGMENT

The Committee on Infectious Diseases gratefully acknowledges Sean O’Leary, MD, MPH, FAAP, for his leadership in drafting the policy statement.

REFERENCES

1. American Academy of Pediatrics, Committee on Infectious Diseases. COVID-19 vaccines in infants, children, and adolescents. *Pediatrics*. 2022;150(3):e2022058700. DOI: 10.1542/peds.2022-058700
2. Free RJ, Patel K, Taylor CA, et al. Hospitalization for COVID-19 and risk factors for severe disease among children: 2022-2024. *Pediatrics*. Published online July 3, 2025. DOI: 10.1542/peds.2025-072788
3. Centers for Disease Control and Prevention. COVID-19 Hospitalization Surveillance Network (COVID-NET). Accessed August 7, 2025. <https://www.cdc.gov/covid/php/covid-net/index.html>
4. Centers for Disease Control and Prevention, National Center for Health Statistics. Provisional Mortality Statistics. CDC WONDER [database]. Accessed July 29, 2025. <https://wonder.cdc.gov/mcd-icd10-provisional.html>
5. Hause AM, Shay DK, Klein NP, et al. Safety of COVID-19 Vaccination in United States children ages 5 to 11 years. *Pediatrics*. 2022;150(2):e2022057313. DOI: 10.1542/peds.2022-057313
6. Hause AM, Marquez P, Zhang B, et al. Safety monitoring of mRNA COVID-19 vaccine third doses among children aged 6 months–5 years—United States, June 17, 2022–May 7, 2023. *MMWR Morb Mortal Wkly Rep* 2023;72(23):621–626. DOI: 10.15585/mmwr.mm7223a2
7. Hesse EM, Hause A, Myers T, et al. COVID-19 vaccine safety first year findings in adolescents. *Pediatrics*. 2023;151(5):e2022060295. DOI: 10.1542/peds.2022-060295
8. Hause AM, Marquez P, Zhang B, et al. Safety monitoring of bivalent COVID-19 mRNA vaccine booster doses among children aged 5–11 years—United States, October 12–January 1, 2023. *MMWR Morb Mortal Wkly Rep* 2023;72(2):39–43. DOI: 10.15585/mmwr.mm7202a5
9. Hause AM, Marquez P, Zhang B, et al. COVID-19 mRNA vaccine safety among children aged 6 months–5 years—United States, June 18, 2022–August 21, 2022. *MMWR Morb Mortal Wkly Rep* 2022;71(35):1115–1120. DOI: 10.15585/mmwr.mm7135a3

10. Goddard K, Donahue JG, Lewis N, et al. Safety of COVID-19 mRNA vaccination among young children in the Vaccine Safety Datalink. *Pediatrics*. 2023;152(1):e2023061894. DOI: 10.1542/peds.2023-061894
11. Cortese MM, Taylor AW, Akinbami LJ, et al. Surveillance for multisystem inflammatory syndrome in US children aged 5-11 years who received Pfizer-BioNTech COVID-19 vaccine, November 2021 through March 2022. *J Infect Dis*. 2023;228(2):143-48. DOI: 10.1093/infdis/jiad051
12. Yousaf AR, Cortese MM, Taylor AW, et al. Reported cases of multisystem inflammatory syndrome in children aged 12–20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation. *Lancet Child Adolesc Health*. 2022;6(5):303-312. DOI: 10.1016/S2352-4642(22)00028-1
13. Link-Gelles R, Ciesla AA, Rowley EA, et al. Effectiveness of monovalent and bivalent mRNA vaccines in preventing COVID-19–associated emergency department and urgent care encounters among children aged 6 months–5 years — VISION Network, United States, July 2022–June 2023. *MMWR Morb Mortal Wkly Rep*. 2023;72(33):886–892. DOI: 10.15585/mmwr.mm7233a2
14. Yousaf AR, Mak J, Gwynn L, et al. COVID-19 vaccination and odds of post–COVID-19 condition symptoms in children aged 5 to 17 years. *JAMA Netw Open*. 2025;8(2):e2459672. DOI: 10.1001/jamanetworkopen.2024.59672
15. Hamad Saied M, van der Griend L, van Straalen JW, et al. The protective effect of COVID-19 vaccines on developing multisystem inflammatory syndrome in children (MIS-C): a systematic literature review and meta-analysis. *Pediatr Rheumatol*. 2023;21(1):80. DOI: 10.1186/s12969-023-00848-1
16. Roper LE, Godfrey M, Link-Gelles R, et al. Use of additional doses of 2024–2025 COVID-19 vaccine for adults aged ≥ 65 years and persons aged ≥ 6 months with moderate or severe immunocompromise: recommendations of the Advisory Committee on Immunization Practices—

United States, 2024. *MMWR Morb Mortal Wkly Rep* 2024;73(49):1118–1123.

DOI: 10.15585/mmwr.mm7349a2

17. Yek C, Warner S, Wiltz JL, et al. Risk factors for severe COVID-19 outcomes among persons aged ≥ 18 years who completed a primary COVID-19 vaccination series—465 health care facilities, United States, December 2020–October 2021. *MMWR Morb Mortal Wkly Rep* 2022;71(1):19-25. DOI: 10.15585/mmwr.mm7101a4
18. National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention. Use of 2025-2026 COVID-19 Vaccines: Work Group Considerations. Accessed August 7, 2025. <https://www.cdc.gov/acip/downloads/slides-2025-04-15-16/05-Panagiotakopoulos-COVID-508.pdf>